[A loco-regional cancer chemotherapy, using a fibrin clot as a drug carrier--the oncolytic effects and putative mechanisms].
Anticancer drug (AD), adriamycin (ADM) or cisplatinum (CDDP) were individually encapsulated into an insoluble fibrin clot (FC), using our own technique. FC-ADM or FC-CDDP was intraabdominally placed in AH 130-bearing rats, and ADM or CDDP solution was intraabdominally injected (IP) into other cancer-bearing rats. The survival time was recorded and related oncolytic mechanisms were investigated. Eleven of 14 rats treated with FC-CDDP, and four of eight rats given FC-ADM, survived for more than 200 days. In these animals, the ascites disappeared within 10 to 14 days after the treatment, and there was neither a recurrence of ascites nor metastases. Eight of these rats underwent challenge of AH 130 cells. All the challenged animals revealed no evidence of recurrence of the cancer and showed a killing activity against the AH 130 cancer cells. Survival time in the other cancer-bearing rats was shorter than three weeks, and the direct cause of death was cachexia. Our newly devised FC-AD showed high activity against implanted AH 130 tumors. These activities are attributed to both a sustained release of AD and immunoresponses induced with FC-AD.
Sugitachi
A
A
Dept. of Surgery, Osaka National Hospital.
Kohayakawa
K
K
Kawahara
T
T
Shindo
T
T
D000818:Animals; D002945:Cisplatin / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage*; D004337:Drug Carriers; D005337:Fibrin / Q000008:administration & dosage*; D007263:Infusions, Parenteral; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008297:Male; D011379:Prognosis; D051381:Rats; D011919:Rats, Inbred Strains
D004337:Drug Carriers; D004317:Doxorubicin; D005337:Fibrin; D002945:Cisplatin